Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous LNL in HER2-Negative Breast Cancer
NCT05981014Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Aug 2023
- Primary completion
- Dec 2030
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tumor-draining lymph node-derived lymphocytes in breast cancer (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Incidence of Dose-Limiting Toxicity at 28 days, Incidence of Grade >=3 Treatment-Emergent Adverse Event at 28 days and 1 more. Started Aug 2023; status: recruiting.
02
Drugs
tumor-draining lymph node-derived lymphocytes
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05981014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05981014.